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Abstract
Aldose reductase (AKR1B1) is a critical drug target due to its involvement in diabetic complications, inflammation and tumorigenesis. However, to date, development of clinically useful inhibitors has been largely unsuccessful. Cyclopentenone prostaglandins (cyPGs) are reactive lipid mediators that bind covalently to proteins and exert anti-inflammatory and antiproliferative effects in numerous settings. By pursuing the targets for modification by cyPGs we have found that the cyPG PGA 1 binds to and inactivates AKR1B1. A PGA 1 -AKR1B1 adduct was observed, both by MALDI-TOF MS and by SDS-PAGE using biotinylated PGA 1 (PGA 1 -B). Insight into the molecular interactions between AKR1B1 and PGA 1 was advanced by molecular modeling. This anticipated the addition of PGA 1 to active site Cys298 and the potential reversibility of the adduct, which was supported experimentally. Indeed, loss of biotin label from the AKR1B1-PGA 1 -B adduct was favored by glutathione, indicating a retro-Michael reaction, which unveils new implications of cyPGprotein interaction. PGA 1 elicited only marginal inhibition of aldehyde reductase (AKR1A1), considered responsible for the severe adverse effects of many AKR1B1 inhibitors.
Interestingly, other PGs, including non-electrophilic PGE 1 and PGE 2 , currently used in the clinical practice, inhibited the enzyme. Moreover, both PGA 1 and PGE 1 reduced the formation of sorbitol in an ex-vivo model of diabetic cataract to extents comparable to those attained by the known AKR inhibitor epalrestat. Taken together, these results highlight the role of PGs as AKR1B1 inhibitors and the interest of PG-related molecules as leads for the development of novel pharmacological tools.
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Introduction
Enzymes of the Aldo-Keto Reductase (AKR) family metabolize various aldehydes using NAD(P)(H) as a cofactor. Although they play a protective role under physiological situations, their increased activity is considered a pathogenic factor (Alexiou et al., 2009 ).
Aldose reductase (AKR1B1) is an important mediator of inflammation and diabetic complications (Alexiou et al., 2009; Laffin and Petrash, 2012; Srivastava et al., 2011) .
AKR1B1 metabolizes reactive aldehydes, like 4-hydroxy-trans-2-nonenal (Ramana et al., 2006) yielding products that perpetuate inflammation . AKR1B1 has also been involved in allergic inflammation and asthma (Yadav et al., 2013; Yadav et al., 2011) . Moreover, AKR1B1 participates in the metabolism of certain prostaglandins (PGs), thus regulating the generation of inflammatory or vasoactive mediators (Kabututu et al., 2009; Michaud et al., 2014) .
AKR1B1 metabolizes glucose through the polyol pathway producing sorbitol. In hyperglycemia this provokes sorbitol accumulation, inducing osmotic stress, favoring epithelial-mesenchymal transition (Ko et al., 1997; Zhang et al., 2012) , and contributing to fibrosis, diabetic cataract, and vasculopathy (Hashim and Zarina, 2012; Lai et al., 2013) . In addition, increased AKR1B1 activity depletes NADPH required for cellular antioxidant defenses and detoxifying systems (Pollak et al., 2007b) , thus increasing susceptibility to oxidative stress (Pollak et al., 2007a; Ying, 2008) . Moreover, AKR1B1 can elicit a proinflammatory and prothrombotic state in diabetes through oxidative stress (Tang et al., 2011) or Egr-1 hyperacetylation and activation (Vedantham et al., 2014) .
Consequently, the search for AKR1B1 inhibitors is an active field of research. However, the clinical use of various compounds, including tolrestat (Drugbank ID DB02383) and sorbinil (Drugbank ID DB02712) has been hampered by their poor effectiveness and severe adverse effects, such as hepatitis or renal toxicity, attributed to inhibition of the related enzyme aldehyde reductase (AKR1A1 or ALR1) (Muthenna et al., 2009) . Therefore, inhibitor selectivity for AKR1B1 over AKR1A1 is preferred over inhibitory potency if it implies less side effects (Suzen and Buyukbingol, 2003) .
This article has not been copyedited and formatted. The final version may differ from this version. cyPGs are electrophilic compounds that form Michael adducts with proteins, mainly at cysteine residues located in favorable environments (Garzón et al., 2011; Oeste and Pérez-Sala, 2014) . cyPGs bind to and modulate transcription factors (Cernuda-Morollón et al., 2001 ; Kim and Surh, 2006; Pérez-Sala, 2011) , activate the antioxidant response (Levonen et al., 2004; Martínez et al., 2012) , inactivate detoxifying enzymes, like glutathione transferases (Sánchez-Gómez et al., 2010) , and induce anti-inflammatory and antiproliferative effects (Díez-Dacal and Pérez-Sala, 2012) , for which they have been proposed as therapeutic tools (Fukushima et al., 2001; Homem de Bittencourt et al., 2007) .
Recently, we identified several AKRs as potential targets for the cyPG PGA 1 Preparation of aldose reductase (ALR2 or AKR1B4) from rat lens. AKR1B4 from rat lens was partially purified using a procedure as follows: lenses were quickly removed from rats following euthanasia and homogenized in a glass homogenizer with a teflon pestle in 5 volumes of cold distilled water. The homogenate was centrifuged at 10,000 x g at 0-4°C for 20 min. The supernatant was precipitated with saturated ammonium sulfate at 40 %, 50 % and then at 75 % salt saturation. The supernatant was retained after the first two precipitations. The pellet from the last step, possessing AKR1B4 activity, was
This article has not been copyedited and formatted. The final version may differ from this version. For assay of AKR1B4 and AKR1A3 partially purified preparations from rat tissues the following procedures were followed: To determine AKR1B4 activity, the reaction mixture Determination of sorbitol formation by isolated rat lenses. A previously described protocol was used (Chatzopoulou et al., 2011) , with the exception that Sigma M-199 (M 3769) was used as an incubation medium at pH 7.4. Briefly, freshly dissected lenses were incubated individually in 1.5 ml of M-199 medium for 3 h at 37ºC, into which 5% CO 2 , 95%
O 2 was bubbled at regular intervals. PGA 1 prepared in DMSO was added to incubation mixtures in such a way that the final DMSO concentration in all incubations was 1%.
Incubations were terminated by placing the mixtures on ice, washing the eye lenses with PBS and freezing them at -80ºC until analysis. For sorbitol measurement, thawed eye lenses were homogenized in distilled water and subjected to precipitation with ice-cold Protonation of titratable groups and assignment of AMBER leaprc.ff14SB force-field parameters was performed as described previously . Atom charges for free and Cys298-bound PGA 1 atoms were obtained by fitting the quantum mechanically calculated (RHF 6-31G*\\3-21G*) molecular electrostatic potential to a point charge model, as implemented in Gaussian 03 (Gaussian, Inc.) using the R.E.D. server 1 1 achieve electroneutrality. Unrestrained molecular dynamics simulations were run for 20 ns using the AMBER force field under periodic boundary conditions and program pmemd as implemented in the AMBER14 suite (Case et al., 2015) . Program Glide (Schrödinger, SL) was used for docking glutathione (GSH) and the final binding mode was refined after selecting 3 conformations of covalently bonded PGA 1 .
Statistical analysis. All assays were repeated at least three times. Statistical significance was evaluated by a parametric Student´s t-test for independent samples.
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 1A ). An IC50 of 15.9 ± 7.4 μM (average of 4 assays ± SEM) was obtained. Inhibition of AKR1B1 by PGA 1 was also timedependent. AKR1B1 was incubated with PGA 1 (20 μM) for increasing times and the preincubation mixture was diluted 1:10 prior to enzyme assay. Under these conditions, close to 40% inhibition of the enzymatic activity was observed after a 2 h pre-incubation with PGA 1 (Fig. 1B) , indicating an inactivation of the enzyme. To provide further evidence for this effect, AKR1B1 was incubated with increasing concentrations of PGA 1 for 2 h, after which, enzyme activity was assayed maintaining the concentration of PG in the assay mixture or diluting it 10 times (Fig. 1C) . Consistent with the previous results, dilution of the PG in the assay partially improved but did not completely restore enzyme activity (Fig. 1C) . Thus, for any given concentration of the PG in the assay the degree of inhibition observed was always higher when the enzyme had been pre-incubated with a 10-fold PG excess. These results indicate that PGA 1 inactivates AKR1B1.
PGA 1 binds covalently to AKR1B1. To assess the possibility of a covalent interaction between PGA 1 and AKR1B1, we first analyzed PGA 1 -binding to AKR1B1 by MALDI-TOF MS ( Fig. 2A) . The intact control protein was observed at m/z 35686.1. In the presence of PGA 1 we observed a mass shift of 336.9, compatible with the formation of a complex between one PGA 1 molecule (mass 336.5 Da) and AKR1B1. PGA 1 binding was stable even after incubation in the presence of 5 M guanidinium chloride and subsequent purification by ZipTip ( Fig. 2A, lower panel) . In addition, incubation of AKR1B1 with the biotinylated analog of PGA 1 (PGA 1 -B) resulted in the formation of a complex that could be detected under denaturing conditions, as assessed by SDS-PAGE followed by protein transfer and biotin detection with HRP-coupled streptavidin (Fig. 2B) . These results firmly support the covalent nature of the PGA 1 -AKR1B1 complex.
Molecular modeling of PGA 1 -AKR1B1 interaction. In our previous study we proposed a three-dimensional molecular model for the pre-covalent complex between PGA 1 and This article has not been copyedited and formatted. The final version may differ from this version. AKR1B1 . We suggested that PGA 1 was likely to share some binding features with several known inhibitors which have been co-crystallized with AKR1B1, the most prominent being that the cyclopentenone oxygen (O9) of PGA 1 , in analogy to the carboxylate of many of these inhibitors, can accept hydrogen bonds from both the Nε of His111 and the hydroxyl of Tyr49 (Fig. 3) . In such an arrangement, the β -carbon of the α,β-unsaturated system in PGA 1 (C11) is activated and able to react with the attacking sulfur of Cys298 to yield the corresponding Michael adduct (Fig. 3A) . The reaction mechanism would first proceed with the formation of an enolate intermediate which would then evolve to the keto form following protonation at C10. Although addition of cyPGs to cysteine residues is considered virtually irreversible in biological systems, theoretically, this reaction can proceed in both ways. In fact, in the case of GSTp, excess glutathione (GSH) has been proposed to facilitate the retro-Michael reaction of a GSTp-PGA 2 adduct (van Iersel et al., 1999) . Therefore, we assessed the feasibility of GSH binding to the AKR1B1(Cys298-PGA 1 ):NADP + ternary complex using molecular modeling. Our results
showed that the attacking sulfur group in GSH can indeed gain access to C11 of PGA 1 and therefore, this metabolite could reverse the covalent binding of PGA 1 to the enzyme through a Michael addition (Fig. 3B) . Remarkably, the reversibility could be confirmed experimentally by incubating the AKR1B1-PGA 1 -B adduct in the presence of excess GSH.
This induced a loss of the biotin signal associated with AKR1B1 that is indicative of a decrease in the concentrations of adduct (Fig. 4A) . Complementarily, an excess nitrobenzyl-glutathione analog (NBG), in which the thiol group of glutathione is blocked, did not show this effect (Fig. 4B ). It is noteworthy that when the PGA 1 -B adduct of the AKR1B10 isoform was likewise incubated with GSH, the biotin signal was also reduced (Fig. 4C ).
These results suggest that the covalent PGA 1 -AKR1B1 adduct may be reversible under certain conditions and that this behavior may be shared by other members of the AKR family, given the high degree of conservation of the catalytic residues.
Next, we attempted to confirm the binding site of PGA 1 to AKR1B1 using several strategies.
The first one relied on direct MS analysis of modified recombinant AKR1B1 using both MALDI/MS and LC-MS/MS approaches. AKR1B1 was incubated with PGA 1 and protein This article has not been copyedited and formatted. The final version may differ from this version. Figure 5A ). In addition, we observed several peaks compatible with PGA 1 addition at Cys303, suggesting that the 1498.1 peptide may contain a mixture of both species. Moreover, the ion corresponding to the retro-Michael fragmentation of the modified peptide (m/z 1161.5) as well as the ions corresponding to the free cysteines, were detected. Thus, although using this approach we can observe modification of cysteine residues by PGA 1 , binding is not fully stable under the conditions of the analysis and does not allow to ascertain the potential selectivity of the modification. Moreover, the isolated peptide cannot mimic the complex interactions taking place in the full-length protein. Therefore, to strengthen the hypothesis that PGA 1 binds at the active site Cys298 we performed a competition assay with GSNO, which has been shown to specifically target Cys298 by inducing its glutathionylation (Baba et al., 2009) (Fig. 7A ). AKR1B1 incubated in the presence of PGE 2 showed a displacement of the centroid of the protein by 349.6 Da, which is compatible with the formation of a PGE 2 -AKR1B1 complex (mass of PGE 2 , 352.5) (Fig. 7A, upper panel) . This complex was stable after addition of 1.5 M guanidinium chloride and ZipTip purification. However, in contrast to what was observed with PGA 1 , binding of PGE 2 was lost after addition of 5 M guanidinium chloride and subsequent purification on ZipTip (Fig. 7A, lower panel) . Furthermore, incubation of AKR1B1 with biotinylated PGE 2 did not result in an adduct stable under SDS-PAGE denaturing conditions (Fig. 7B) . Thus, these observations suggest that PGE also interacts with the enzyme active site, although through a non-covalent interaction.
Consistent with this, incubation of AKR1B1 with an excess PGA 1 or PGE 2 reduced its modification by PGA 1 -B (Fig. 7C, left panels) . However, when the excess of competing PG was removed prior to addition of PGA 1 -B the blocking effect of PGE 2 was abolished whereas that of PGA 1 persisted (Fig. 7C, right panels) . These results indicate that some PGs may tightly bind to AKR1B1 in such a way that the complex is stable under the This article has not been copyedited and formatted. The final version may differ from this version. Fig. 8 ). Moreover, the inhibition was not concentration-dependent, which precluded the calculation of an IC50 value. Similar results were obtained using enzymes from different sources, namely, the recombinant enzyme and the enzyme purified from rat kidney. In the case of rat kidney aldehyde reductase, the percentage inhibition by 100 μM PGA 1 was 18.8% ± 3.1 (average ± SD of 6 determinations) without preincubation, and 17.8% ± 1.2 (average ± SD of 3 determinations), after 1 h preincubation. Therefore, preincubation with PGA 1 did not influence the extent of inhibition. Thus, PGA 1 displays high selectivity for AKR1B1 versus AKR1A1.
Studies with aldose reductase (AKR1B4) from rat lens. To obtain insight into the potential beneficial effects of inhibiting AKR1B1 in a biological system, we studied rat lenses as a model in which AKR1B4 activity has been involved in the development of diabetic cataract . PGA 1 effectively inhibited AKR1B4 isolated from rat lens with an IC50 of 4.1 ± 1.1 μM. Also in this case, preincubation of the enzyme preparation with the PG inactivated the enzyme, as deduced from the stronger inhibition the effect of PGA 1 on AKR1B4 activity in intact rat lenses by measuring the formation of sorbitol from glucose (Fig. 9) . Incubation of intact lenses in a glucose enriched medium increased the formation of sorbitol. Interestingly, PGA 1 inhibited glucose-stimulated sorbitol formation in a concentration-dependent manner (Fig. 9A) , showing a potency similar to that of other known inhibitors of AKRs like epalrestat (Fig. 9C) . Moreover, PGE 1 was also an effective inhibitor in this system (Fig. 9B) . Interestingly, PGE and PGE analogs are currently used for the treatment of various ocular pathologies, including glaucoma and ischemia (Alm, 2014; Steigerwalt et al., 2010) . Since AKR inhibitors have been envisaged as potential therapeutic tools for ocular diabetic complications, the definition of PGs as inhibitors of AKR1B1 encourages the study of their potential usefulness for these conditions.
This article has not been copyedited and formatted. The final version may differ from this version. CyPGs modify a plethora of cellular proteins mainly at cysteine residues. However, their binding does not occur randomly; rather it is determined by structural features of the protein and the cyPG and by context factors. Aldose reductase was identified as a selective target for PGA 1 in murine fibroblasts, in which AKR enzymes appeared as the main cytosolic PGA 1 -B-modified proteins . Here we show that the major product of AKR1B1-PGA 1 interaction consists of a covalent adduct which incorporates one PG molecule. Thus, although AKR1B1 possesses seven cysteine residues, apparently only one is modified by PGA 1 . Despite unsuccessful attempts to detect the modified peptide by MS analysis, our results are consistent with the hypothesis that PGA 1 interacts with Cys298, which occupies a key position in the active site of AKR1B1 (Balendiran et al., 2011) . This is based on analogy with AKR1B10, which is modified at the equivalent Cys299, as detected by both MS (Díez-Dacal, unpublished results) and site directed mutagenesis .
Cys298 of AKR1B1 has been shown to be the target for various oxidative modifications that are responsible for a complex regulation of AKR1B1 activity. Thus, some modifications, like S-nitrosylation or alkylation, may even increase the activity of the enzyme in vitro, whereas glutathionylation is inhibitory (Kaiserova et al., 2006; Srivastava et al., 2003) . In vivo, sufenylation of the active site cysteines, Cys298 and Cys303, a modification potentially secondary to S-nitrosylation, has been proposed to mediate the increase in AKR1B1 enzyme activity observed in the ischemic heart (Baba et al., 2009 ). Therefore, it seems that the functional consequences of the modification depend on the size or the structure of the modifying moiety. Covalent addition of cyPGs to cysteine residues requires the thiol group to be in its free thiolate form. Thus, other oxidative modifications of AKR1B1, including disulfide formation with the neighboring Cys303, will preclude covalent binding of PGA 1 .
Interestingly, although cyPG addition is considered irreversible under physiological conditions (Suzuki et al., 1997 ), our results demonstrate that the AKR1B1-PGA 1 adduct is not stable in the presence of millimolar GSH concentrations. Our molecular model shows that, although the binding of PGA 1 to the active site of AKR1B1 prevents the entry of GSH into the anion binding site (Singh et al., 2006) , the GSH thiol group is accessible to C11 of PGA 1 and therefore, it could react with the cyPG and revert the covalent adduct (Fig. 3b) , which is in accordance with our experimental results. These observations reinforce the importance of GSH levels as modulators of cyPG-induced protein modification and regulation, observed in several experimental models Gayarre et al., 2005; Straus et al., 2000) . Moreover, they grant the study of the reversibility of other cyPG-or electrophilic lipid-protein adducts and the reevaluation of their potential regulatory
importance.
An interesting aspect of PGA 1 is its high selectivity towards AKR1B1 versus AKR1A1, which is an important index for the adequacy of potential inhibitors. Inhibition of AKR1A1, also known as aldehyde reductase or ALR1, may result in skin reactions and liver toxicity presence of NADPH (Michaud et al., 2014) , whereas in its absence it may catalyze its isomerization to PGD 2 , which is a precursor for the J series of cyPGs (Nagata et al., 2011) .
In this context, our findings that several PGs bind and inhibit the enzyme may be highly relevant in pathophysiological settings. In the case of PGE 2 it is interesting to note that the enzyme-PG complex is stable enough as to be observed by MALDI-TOF MS under mild denaturing conditions, although is lost after removal of excess PG and under strong denaturing conditions, such as those used for SDS-PAGE or incubation in high guanidinium chloride concentrations. IC50 values obtained for most PGs were in the micromolar range.
The differences found between IC50 values for recombinant AKR1B1 and the purified rat lens enzyme are likely due to differences in enzyme preparation and/or assay conditions.
The pathophysiological implications of AKR1B1 continue to expand. Besides its widely accepted role in the development of diabetic complications, AKR1B1 has been recently involved in tumorigenesis and in allergic responses (Yadav et al., 2013) . The fact that AKR1B1 activity can be regulated by PGs poses interesting questions in this context.
Remarkably, PGE 2 has been reported to exert protective effects in asthma, mainly through interaction with the PGE receptor (Torres et al., 2015) , but an implication of AKR1B1 in these effects has not been explored. It would be relevant to assess whether AKR1B1 can be modulated by endogenously generated PGs and if so, if this influences inflammatory or allergic responses. Importantly, genetic alterations can provide additional pathophysiological implications of AKR1B1. Indeed, several polymorphisms of the AKR1B1 gene have been associated with the development of diabetic complications (Abhary et al., 2010; Demaine, 2003) . Nevertheless, an association of these or other polymorphisms with tumorigenesis or inflammatory allergic conditions has not been reported to date. Studies are under way to explore these possibilities.
One of the most common diabetic complications is the development of diabetic cataracts.
AKR1B1 has long been involved in lens opacification in situations of hyperglycaemia (Narayanan, 1993) . AKR1B1 has been identified as a risk factor for cataract. Experimental aldose reductase overexpression in the lens accelerates the development of cataracts in This article has not been copyedited and formatted. The final version may differ from this version. (Snow et al., 2015) , whereas knockdown of the enzyme in rats protects from lens opacification ex vivo . In addition, strategies using inhibitors have provided numerous pieces of evidence for the implication of AKR1B1 in diabetic cataract in various experimental models. Thus, topical administration of an aldose reductase inhibitor delays the development of cataracts in diabetic dogs (Kador et al., 2010) , whereas oral treatment with another inhibitor prevents their progression in rats (Kawakubo et al., 2012) . The results herein presented show that both PGA 1 and PGE 1 reduce the formation of sorbitol in isolated rat lenses exposed to high glucose, thus opening the way for in vivo studies. Interestingly, the extent of inhibition attained by PGs is similar to that of the well-known AKR inhibitor epalrestat, which has a considerable lower IC50 value in vitro. Therefore, the possibility exists that a better penetrance or a more stable interaction with the enzyme favor the efficacy of PGs in this biological system.
Interestingly, some of the PGs assayed, including PGE 1 (alprostadil) and its analog, limaprost, are currently used in the clinical practice as vasodilators, and beneficial effects of these agents have been documented in age-related macular degeneration (Augustin et al., 2013) and in intermittent claudication (Nakanishi et al., 2008) Incubation mixtures were split into two aliquots and one of them was subjected to gel filtration on Zeba desalting micro-spin columns to remove excess PG (left panels).
Subsequently, 1 μM PGA 1 -B was added and incubation was continued for 90 min at r. 
